Leiner Asks FDA About Restarting U.S. OTC Operations, Posts $27.5 Mil. Loss
This article was originally published in The Tan Sheet
Executive Summary
Heightened concerns over product quality triggered by adulterated Chinese imports and the need for more than one U.S. private-label supplier are fueling Leiner Health Products' optimism as it prepares to reenter the OTC market and recover from setbacks that led to a $27.5 million net loss in its latest quarter, CEO Robert Kaminski said Aug. 14